California Public Employees Retirement System held its stake in Proteostasis Therapeutics Inc (NASDAQ:PTI) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,200 shares of the company’s stock at the close of the second quarter. California Public Employees Retirement System owned about 0.16% of Proteostasis Therapeutics worth $193,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the stock. LMR Partners LLP purchased a new stake in Proteostasis Therapeutics in the 2nd quarter worth about $127,000. Bank of New York Mellon Corp raised its position in Proteostasis Therapeutics by 17.3% in the 1st quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock worth $273,000 after purchasing an additional 5,153 shares during the period. Jennison Associates LLC raised its position in Proteostasis Therapeutics by 6.2% in the 2nd quarter. Jennison Associates LLC now owns 2,075,439 shares of the company’s stock worth $9,713,000 after purchasing an additional 120,575 shares during the period. Finally, FMR LLC raised its position in Proteostasis Therapeutics by 2.3% in the 2nd quarter. FMR LLC now owns 2,944,915 shares of the company’s stock worth $13,782,000 after purchasing an additional 66,111 shares during the period. 68.08% of the stock is owned by hedge funds and other institutional investors.

PTI has been the topic of a number of recent analyst reports. Leerink Swann reissued an “outperform” rating and issued a $9.00 price objective (down from $17.00) on shares of Proteostasis Therapeutics in a research report on Wednesday, August 16th. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th.

Shares of Proteostasis Therapeutics Inc (NASDAQ PTI) opened at $2.52 on Friday. Proteostasis Therapeutics Inc has a 1 year low of $1.41 and a 1 year high of $16.67.

Proteostasis Therapeutics (NASDAQ:PTI) last issued its earnings results on Tuesday, November 14th. The company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.16. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. research analysts predict that Proteostasis Therapeutics Inc will post -2.47 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Proteostasis Therapeutics Inc (PTI) Stake Maintained by California Public Employees Retirement System” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/proteostasis-therapeutics-inc-pti-stake-maintained-by-california-public-employees-retirement-system/1738661.html.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Want to see what other hedge funds are holding PTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Proteostasis Therapeutics Inc (NASDAQ:PTI).

Institutional Ownership by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.